Payment overview · 2025
General Payments
$398.72
16 reported records · 8 companies
Healthcare provider profile · identity verified
Thomas P Lenns, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HILTON HEAD ISLAND, SC · NPI 1780778555
Verified facts
What the public records show
CMS Open Payments records show Thomas P Lenns, M.D. received $398.72 in general payments during 2025 across 16 reported records.
Novartis Pharmaceuticals Corporation accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Ozempic, Prolia, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $90.52 | 22.7% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $82.04 | 20.6% | 3 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $71.44 | 17.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $40.86 | 10.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.77 | 9.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.32 | 8.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.52 | 5.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.25 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.72 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $82.04 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $62.02 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.32 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 370 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 225 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 72 |
| Eliquis | Apixaban | 201 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 46 |
| Alprazolam | Alprazolam | 152 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 38 |
| Simvastatin | Simvastatin | 138 | 39 |
| Lisinopril | Lisinopril | 136 | 37 |
| Irbesartan | Irbesartan | 123 | 33 |
| Gabapentin | Gabapentin | 109 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 41 |
| Prednisone | Prednisone | 105 | 56 |
| Losartan Potassium | Losartan Potassium | 102 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 40 |
| Tramadol Hcl | Tramadol Hcl | 96 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 59 |
| Azithromycin | Azithromycin | 85 | 67 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 60 |
| Metformin Hcl | Metformin Hcl | 82 | 26 |
| Valsartan | Valsartan | 82 | 22 |
| Omeprazole | Omeprazole | 80 | 26 |
| Furosemide | Furosemide | 76 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 25 |
| Mounjaro | Tirzepatide | 68 | suppressed |
| Celecoxib | Celecoxib | 66 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 19 |
| Synthroid | Levothyroxine Sodium | 66 | 17 |
| Myrbetriq | Mirabegron | 64 | 14 |
| Allopurinol | Allopurinol | 63 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 15 |
| Sertraline Hcl | Sertraline Hcl | 53 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 18 |
| Atenolol | Atenolol | 50 | 14 |
| Lorazepam | Lorazepam | 50 | suppressed |
| Ozempic | Semaglutide | 48 | suppressed |
| Meloxicam | Meloxicam | 46 | 22 |
| Cephalexin | Cephalexin | 45 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Carvedilol | Carvedilol | 42 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 16 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 12 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 14 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Levofloxacin | Levofloxacin | 29 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 19 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 11 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.72 · 16 records | Novartis Pharmaceuticals Corporation | ENTRESTO, EVENITY, FREESTYLE LIBRE 3, GEMTESA, LEQVIO, Leqembi, Ozempic, PROLIA, REXULTI, Rybelsus | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error